Comparative Pharmacology
Head-to-head clinical analysis: COR OTICIN versus CORMAX.
Peer-Reviewed Evidence
Head-to-head clinical analysis: COR OTICIN versus CORMAX.
COR-OTICIN vs CORMAX
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
COR-OTICIN is a combination product containing hydrocortisone (a corticosteroid with anti-inflammatory and immunosuppressive properties) and neomycin (an aminoglycoside antibiotic that inhibits bacterial protein synthesis by binding to the 30S ribosomal subunit) and polymyxin B (a polymyxin antibiotic that disrupts bacterial cell membrane permeability).
Corticosteroid with anti-inflammatory, antipruritic, and vasoconstrictive effects. Binds to glucocorticoid receptors, modulating gene expression to inhibit phospholipase A2, reduce prostaglandin and leukotriene synthesis, and suppress cytokine release.
1-2 drops in each affected ear twice daily for 7 days.
2.5 mg orally twice daily; maximum 10 mg/day.
None Documented
None Documented
Terminal half-life 4-6 hours; prolonged in renal impairment (up to 12-15 hours)
Terminal elimination half-life: 3.5 hours (range 2.5-4.5 h); clinical context: dosing every 4-6 hours to maintain therapeutic levels
Renal (60-80% unchanged), fecal/biliary (5-10%)
Renal: 90% unchanged; minor biliary/fecal: <5%
Category C
Category C
Topical Corticosteroid + Antibiotic
Topical Corticosteroid